We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism (ZA-003Ext)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01067365
First Posted: February 11, 2010
Last Update Posted: June 27, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Repros Therapeutics Inc.
February 10, 2010
February 11, 2010
June 27, 2014
March 2006
May 2007   (Final data collection date for primary outcome measure)
Evaluate the safety of Androxal™ administered in men with secondary hypogonadism [ Time Frame: One year ]
Evaluate the safety of Androxal™ administered in men with secondary hypogonadism [ Time Frame: Six months ]
Complete list of historical versions of study NCT01067365 on ClinicalTrials.gov Archive Site
Not Provided
Demonstrate that treatment of men with secondary hypogonadism with Androxal™ was non-inferior to treatment with the active control, AndroGel® [ Time Frame: Six months ]
Not Provided
Not Provided
 
Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism
An Open-Label, Multiple Center Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism Who Completed ZA-003
Subjects who completed ZA-003 were eligible to receive an additional year of treatment in this extension study.
The objectives of this study were to evaluate the safety and efficacy of Androxal® administered orally once daily for one year in men with secondary hypogonadism and who had completed ZA-003.
Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Secondary Hypogonadism
  • Drug: Androxal
    12.5 mg once daily
    Other Name: Enclomiphene citrate
  • Drug: Androxal
    25 mg once daily
    Other Name: Enclomiphene citrate
  • Experimental: 12.5 mg Androxal
    12.5 mg Androxal daily
    Intervention: Drug: Androxal
  • Experimental: 25 mg Androxal
    25 mg Androxal daily
    Intervention: Drug: Androxal
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
104
May 2007
May 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Total serum testosterone concentrations < 300 ng/dL at baseline

Exclusion Criteria:

  • Presence or history of prostate cancer
  • Elevated PSA > 3.5 ng/mL

Additional inclusion and exclusion criteria may apply.

Sexes Eligible for Study: Male
18 Years to 68 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01067365
ZA-003 Extension Study
No
Not Provided
Not Provided
Repros Therapeutics Inc.
Repros Therapeutics Inc.
Not Provided
Study Director: Andre van As, MD, PhD Repros Therapeutics Inc.
Repros Therapeutics Inc.
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP